Get to know how CESI-MS will allow you to quickly and accurately characterize protein therapeutics for attributes in a single method by downloading this discovery kit.
Tags
The whys behind the dos and don’ts of oligonucleotide analysis
We know that LC-MS oligonucleotide analysis can have its share of challenges—challenges with sensitivity, challenges with adduct formation and challenges with data analysis, to name just a few. That’s why this blog takes a closer look at the dos and don’ts of this type of analysis and explores some keys to success. It also explains why following these simple rules can vastly improve your oligonucleotide characterization and quantitation efficiency and success.
Top 7 Echo® MS system customer questions—answered
You asked, we answered! With analysis speeds of at least 1 sample per second, the Echo® MS system has created a buzz in the industry. This is up to 50x faster than conventional LC-MS/MS. This revolutionary tool for drug discovery and development has led to...
An interview from the Science Explorer about the Echo® MS system
The Science Explorer interviews Neil Walsh from SCIEX to discuss the significant application areas of the Echo® MS System and what makes this system so attractive to biopharmaceutical laboratories.
The Echo® MS system: Is it reproducible? Yes… yes… yes!
The Echo® MS System is an exciting new platform that dramatically speeds sample analysis for quantitative MS studies. Because of its unique and innovative technology, the system can analyze samples faster than ever before—but without the need for LC.
Scale it up! The Echo® MS System delivers unprecedented levels of productivity
Imagine the productivity gains your lab could achieve with a technology that not only analyzes samples up to 50x faster than conventional quantitative LC-MS, but also eliminates tedious sample preparation, time-consuming LC method development and chromatographic run...
How fast is fast? The Echo® MS System sets the record
How fast is fast? Cheetahs. Usain Bolt. Tachyons. The Echo® MS system. What do these things have in common? They’re all fast. REALLY fast. In fact, they’re the fastest in their categories: the fastest land mammal, the fastest human sprinter, the fastest subatomic...
A new generation of therapeutic modalities
There are over 7,000 genetic diseases that could potentially be cured using gene therapy. Rare metabolic diseases, autoimmune disorders, cardiovascular disease and cancers are some of the top disease classes that can be addressed with gene therapies. With over 1,000...
Enhancing Biologics with CESI-MS Characterization
Comprehensive characterization of a biologic requires analysis at both the intact and digest levels, but these analyses can be complex and cumbersome. For example, with conventional liquid chromatography separations, researchers are often left with limited information...
Full, partial and empty capsid ratios for AAV analysis: What’s the big deal?
For many of you working to develop gene therapy drugs, you know that the time to market the drug is critical. Because gene therapeutics cure diseases by targeting specific genes, it is a constant race to see who develops the drug first. Unlike other classes of drugs where multiple medications can be used to treat a disease, whoever is first to develop a gene therapy drug wins.
Ever thought of breaking the high-throughput sound barrier for drug discovery?
Wouldn’t it be great if we really could “get time back” or even “buy time”? When developing pharmaceuticals, it takes years to bring a new therapy to the market due to the linear nature of the process. As the saying goes, “Time waits for no one.” But what if we could...
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.